Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Zhizhou Liang"'
Autor:
Yichen Zhang, Dingyi Chen, Siyuan Cheng, Zhizhou Liang, Lu Yang, Qian Li, Lin Bai, Huangqianyu Li, Wei Liu, Luwen Shi, Xiaodong Guan
Publikováno v:
PLoS Medicine, Vol 20, Iss 12, p e1004319 (2023)
BackgroundThe use of suboptimal controls in randomized trials of new cancer drugs can produce potentially unreliable clinical efficacy results over the current standard of care and expose patients to substandard therapy. We aim to investigate the pro
Externí odkaz:
https://doaj.org/article/ccc1c0b9972b445aa15ee1851735208a
Publikováno v:
WCNC
Malicious domain detection is of great significance for cybersecurity. Most prior works detect malicious domains based on individual features, which are only related to the attributes of domains themselves and can be easily changed to avoid detection
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9cb51e960866986efbe5d638a2c349ec
https://doi.org/10.1109/wcnc45663.2020.9120488
https://doi.org/10.1109/wcnc45663.2020.9120488
Publikováno v:
Lecture Notes of the Institute for Computer Sciences, Social Informatics and Telecommunications Engineering ISBN: 9783030129804
CollaborateCom
CollaborateCom
Domain name classification is an important issue in the field of cyber security. Notice that objectionable-related domain names are one category of domain names that serve services such as gambling, pornography, etc. They are classified and even forb
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::97bbe459fc1c3bd2b2a791008918227d
https://doi.org/10.1007/978-3-030-12981-1_20
https://doi.org/10.1007/978-3-030-12981-1_20
Autor:
José Salvador Rodrigues de Oliveira, Philipp le Coutre, Zhi Xiang Shen, Israel Bendit, Xiaojun Huang, Sadhvi Khanna, Kudrat Abdulkadyrov, Sandip Shah, Eduardo Bullorsky, Manuel Ayala, Rafik Fellague-Chebra, Tina Owugah, Carmino Antonio De Souza, Tomasz Szczudlo, Zhizhou Liang, Jose Luis Lopez, Jorge E. Cortes, Tomasz Sacha, K Govind Babu
Summary Background Optimal management of patients with chronic myeloid leukaemia in chronic phase with suboptimal cytogenetic response remains undetermined. This study aimed to investigate the safety and efficacy of switching to nilotinib vs imatinib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68078b339f1dc0219f0e967d94164e2d
https://ruj.uj.edu.pl/xmlui/handle/item/94510
https://ruj.uj.edu.pl/xmlui/handle/item/94510
Autor:
K Govind Babu, Xiao-Jun Huang, Sandip Shah, Jorge E. Cortes, Tomasz Sacha, Carmen Piccolo, Zhizhou Liang, Tomasz Szczudlo, Tina Owugah, Philipp le Coutre, Prasanna Kumar Nidamarthy, José Luis López, Israel Bendit, Carmino Antonio De Souza, Eduardo Bullorsky, Manuel Ayala
Publikováno v:
Blood. 122:95-95
Introduction The phase 3 LASOR trial is the only randomized trial that compares the effects of imatinib dose escalation with those of switching to nilotinib in pts with Philadelphia chromosome–positive (Ph+) CML-CP who experience suboptimal respons
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9e621e3109ba45258a6dcd294b4a6f42
https://doi.org/10.1182/blood.v122.21.95.95
https://doi.org/10.1182/blood.v122.21.95.95